MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments

The MEK5-ERK5 pathway is a mammalian mitogen-activated protein (MAP) kinase cascade that is not well studied compared to other MAP kinase cascades. Two independent studies by Al-Ejeh et al. and Ortiz-Ruiz et al. published in Oncotarget last year concluded that ERK5 is an attractive target in triple...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda, Mariska, Rozali, Esdy, Khanna, Kum Kum, Al-Ejeh, Fares
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381702/
https://www.ncbi.nlm.nih.gov/pubmed/25859552
_version_ 1782364503426465792
author Miranda, Mariska
Rozali, Esdy
Khanna, Kum Kum
Al-Ejeh, Fares
author_facet Miranda, Mariska
Rozali, Esdy
Khanna, Kum Kum
Al-Ejeh, Fares
author_sort Miranda, Mariska
collection PubMed
description The MEK5-ERK5 pathway is a mammalian mitogen-activated protein (MAP) kinase cascade that is not well studied compared to other MAP kinase cascades. Two independent studies by Al-Ejeh et al. and Ortiz-Ruiz et al. published in Oncotarget last year concluded that ERK5 is an attractive target in triple negative breast cancer. In this perspective, we briefly describe the findings of these studies and propose the use of pharmacological inhibition of ERK5 in combination with chemotherapy against triple negative breast cancer because MEK5-ERK5 overexpression associates with poor survival of patients treated with chemotherapy.
format Online
Article
Text
id pubmed-4381702
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-43817022015-04-09 MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments Miranda, Mariska Rozali, Esdy Khanna, Kum Kum Al-Ejeh, Fares Oncoscience Research Perspective The MEK5-ERK5 pathway is a mammalian mitogen-activated protein (MAP) kinase cascade that is not well studied compared to other MAP kinase cascades. Two independent studies by Al-Ejeh et al. and Ortiz-Ruiz et al. published in Oncotarget last year concluded that ERK5 is an attractive target in triple negative breast cancer. In this perspective, we briefly describe the findings of these studies and propose the use of pharmacological inhibition of ERK5 in combination with chemotherapy against triple negative breast cancer because MEK5-ERK5 overexpression associates with poor survival of patients treated with chemotherapy. Impact Journals LLC 2015-02-20 /pmc/articles/PMC4381702/ /pubmed/25859552 Text en Copyright: © 2015 Miranda et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Miranda, Mariska
Rozali, Esdy
Khanna, Kum Kum
Al-Ejeh, Fares
MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
title MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
title_full MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
title_fullStr MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
title_full_unstemmed MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
title_short MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
title_sort mek5-erk5 pathway associates with poor survival of breast cancer patients after systemic treatments
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381702/
https://www.ncbi.nlm.nih.gov/pubmed/25859552
work_keys_str_mv AT mirandamariska mek5erk5pathwayassociateswithpoorsurvivalofbreastcancerpatientsaftersystemictreatments
AT rozaliesdy mek5erk5pathwayassociateswithpoorsurvivalofbreastcancerpatientsaftersystemictreatments
AT khannakumkum mek5erk5pathwayassociateswithpoorsurvivalofbreastcancerpatientsaftersystemictreatments
AT alejehfares mek5erk5pathwayassociateswithpoorsurvivalofbreastcancerpatientsaftersystemictreatments

Ejemplares similares